# A simple compound prioritization method for drug discovery considering multi-target binding

**Authors:** Alžbeta Kubincová, David L. Mobley

PMC · DOI: 10.1039/d5dd00464k · Digital Discovery · 2026-02-10

## TL;DR

This paper introduces a new method for drug discovery that considers multiple molecular properties to prioritize compounds more effectively.

## Contribution

The novelty lies in a multiobjective ligand optimization method that efficiently handles expensive-to-compute properties like multi-target binding.

## Key findings

- The method improves retrieval of top binders compared to greedy acquisition by better distributing compute budgets.
- Fitting individual properties separately leads to better rank correlation in predictions.
- The approach supports hit-to-lead and lead optimization by considering binding to multiple targets.

## Abstract

Active learning is an emerging paradigm used to help accelerating drug discovery, but most prior applications seek solely to optimize potency, whereas multiple properties influence a compound's utility as a drug candidate. We introduce a method for multiobjective ligand optimization, which is able to efficiently handle distinct molecular properties that are expensive to compute, such as binding affinities with respect to multiple protein targets. We validate this protocol retrospectively using docking scores, showing an improved retrieval of the top 0.04–0.4% binders from the dataset with our method compared to greedy acquisition, owing to a better distribution of the compute budget between different properties. Our results also suggest that fitting individual properties separately leads to a better rank correlation of the resulting predictions. This workflow addresses the needs of pharmaceutical research for improving the efficiency of hit-to-lead and lead optimization by considering binding to multiple targets. Our code is freely available on Github: https://github.com/MobleyLab/active-learning-notebooks/blob/main/MultiobjectiveAL.ipynb.

Active learning is an emerging paradigm used to help accelerating drug discovery, but most prior applications seek solely to optimize potency, whereas multiple properties influence a compound's utility as a drug candidate.

## Full-text entities

- **Genes:** LCK (LCK proto-oncogene, Src family tyrosine kinase) [NCBI Gene 3932] {aka IMD22, LSK, YT16, p56lck, pp58lck}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, PPARD (peroxisome proliferator activated receptor delta) [NCBI Gene 5467] {aka FAAR, NR1C2, NUC1, NUCI, NUCII, PPARB}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}
- **Diseases:** AL (MESH:D007859), toxicity (MESH:D064420)
- **Chemicals:** octanol (MESH:D000442), water (MESH:D014867), fPPAR (-), hydrogen (MESH:D006859)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12888084/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12888084/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12888084/full.md

---
Source: https://tomesphere.com/paper/PMC12888084